Taylor Financial Group Inc. Purchases 2,699 Shares of Pfizer Inc. (NYSE:PFE)

Taylor Financial Group Inc. lifted its position in Pfizer Inc. (NYSE:PFE) by 23.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 14,175 shares of the biopharmaceutical company’s stock after buying an additional 2,699 shares during the period. Taylor Financial Group Inc.’s holdings in Pfizer were worth $397,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Olistico Wealth LLC purchased a new stake in Pfizer during the 2nd quarter valued at $25,000. MFA Wealth Advisors LLC bought a new position in shares of Pfizer during the second quarter valued at $29,000. Creekmur Asset Management LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at $32,000. Trivant Custom Portfolio Group LLC increased its holdings in Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. purchased a new position in Pfizer in the 2nd quarter worth about $34,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of several research reports. UBS Group raised their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Wells Fargo & Company boosted their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Price Performance

Shares of PFE stock traded up $0.29 on Friday, hitting $29.01. 37,137,599 shares of the stock traded hands, compared to its average volume of 38,496,418. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $36.29. The firm has a 50 day simple moving average of $28.99 and a two-hundred day simple moving average of $28.01. The firm has a market cap of $164.39 billion, a price-to-earnings ratio of -483.50, a PEG ratio of 0.98 and a beta of 0.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period last year, the firm earned $0.67 earnings per share. As a group, equities research analysts predict that Pfizer Inc. will post 2.68 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be given a dividend of $0.42 per share. The ex-dividend date is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.79%. Pfizer’s dividend payout ratio is -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.